231
Views
4
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiometabolic Conditions - Review

A novel option for prandial insulin therapy: inhaled insulin

, , &
Pages 839-847 | Received 15 Apr 2016, Accepted 24 Aug 2016, Published online: 27 Sep 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Marc Rendell. (2019) Premix insulins in type 1 diabetes: the coming of degludec/aspart. Expert Opinion on Drug Metabolism & Toxicology 15:4, pages 341-348.
Read now

Articles from other publishers (3)

Janet B. McGill, Daniel Weiss, Marshall Grant, Marisa C. Jones, David M. Kendall & Byron J. Hoogwerf. (2020) Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. Journal of Diabetes 13:2, pages 164-172.
Crossref
Halis Kaan AkturkJanet K. Snell-BergeonAmanda RewersLeslie J. KlaffBruce W. BodeAnne L. PetersTimothy S. BaileySatish K. Garg. (2018) Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technology & Therapeutics 20:10, pages 639-647.
Crossref
Satish K. GargAmanda H. RewersH. Kaan Akturk. (2018) New Medications for the Treatment of Diabetes. Diabetes Technology & Therapeutics 20:S1, pages S-139-S-153.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.